Trivalent, bispecific antibodies

Patent metadata

Field	Value
Publication number	US-11993642-B2
Application number	US-201916413469-A
Country	US
Kind code	B2
Filing date	May 15, 2019
Priority date	Apr 7, 2009
Publication date	May 28, 2024
Grant date	May 28, 2024

Abstract

The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

First claim

What is claimed is:

1. A nucleic acid encoding a trivalent, bispecific antibody comprising
a) a full length antibody that specifically binds to a first antigen wherein the full length antibody comprises two antibody heavy chains and two antibody light chains, wherein the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface which comprises an alteration in the original interface between the antibody CH3 domains, wherein
i) in the CH3 domain of one heavy chain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain, and wherein
ii) in the CH3 domain of the other heavy chain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which the protuberance within the interface of the first CH3 domain is positionable;
b) a polypeptide comprising
ba) an antibody heavy chain variable domain (VH); or
bb) an antibody heavy chain variable domain (VH) and an antibody constant domain 1 (CH1), wherein the N-terminus of the VH domain of the polypeptide is fused via a peptide connector to the C-terminus of the CH3 domain of one of the two heavy chains of the full length antibody;

c) a polypeptide comprising
ca) an antibody light chain variable domain (VL), or
cb) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL);
wherein the N-terminus of the VL domain of the polypeptide is fused via a peptide connector to the C-terminus of the CH3 domain of the other of the two heavy chains of the full length antibody;

and wherein the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) together form an antigen-binding site specifically binding to a second antigen; and
wherein the peptide connectors under b) and c) are peptides with a length between 5 and 50 amino acids.

2. The nucleic acid of claim 1 , wherein
i) the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W); and
ii) the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V).

3. The nucleic acid of claim 2 , wherein both CH3 domains are further altered by the introduction of cysteine as an amino acid in each CH3 domain such that a disulfide bridge between both CH3 domains can be formed.

4. The nucleic acid of claim 3 , wherein
the CH3 domain under i) comprises a T366W mutation; and
the CH3 domain under ii) comprises T366S, L368A, and Y407V mutations,
wherein the numbering is according to the EU index of Kabat.

5. The nucleic acid of claim 4 , wherein
the CH3 domain under i) comprises Y349C and T366W mutations; and
the CH3 domain under ii) comprises S354C, T366S, L368A, and Y407V mutations,
wherein the numbering is according to the EU index of Kabat.

6. The nucleic acid of claim 1 , wherein
the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) are linked and stabilized via an interchain disulfide bridge by introduction of a disulfide bond between the following positions:
i) heavy chain variable domain (VH) position 44 and light chain variable domain (VL) position 100;
ii) heavy chain variable domain (VH) position 105 and light chain variable domain (VL) position 43; or
iii) heavy chain variable domain (VH) position 101 and light chain variable domain (VL) position 100,
wherein the numbering is according to the EU index of Kabat.

7. The nucleic acid of claim 6 , wherein
the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) are linked and stabilized via an interchain disulfide bridge by introduction of a disulfide bond between heavy chain variable domain (VH) position 44 and light chain variable domain (VL) position 100,
wherein the numbering is according to the EU index of Kabat.

8. The nucleic acid of claim 1 , wherein the peptide connectors under b) and c) are identical peptides with a length between 25 and 50 amino acids.

9. The nucleic acid of claim 1 , wherein the peptide connectors under b) and c) comprise glycine (G) and serine (S) residues.

10. The nucleic acid of claim 9 , wherein the peptide connectors under b) and c) comprise GGGGS (SEQ ID NO: 38) repeats.

Assignees

• Hoffmann La Roche

Inventors

• Brinkmann Ulrich
• Croasdale Rebecca
• Hoffmann Eike
• Klein Christian
• Moessner Ekkehard
• Schanzer Juergen Michael
• Sustmann Claudio
• Umana Pablo

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K16/32

  against translation products of oncogenes · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/31

  multispecific · CPC title